Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.63 USD | -1.49% | -9.57% | -51.87% |
May. 10 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
May. 10 | Sector Update: Health Care | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- The company's enterprise value to sales, at 3.44 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-51.87% | 290M | C+ | ||
+10.79% | 116B | B+ | ||
+11.65% | 106B | B+ | ||
-6.20% | 23.89B | B+ | ||
-2.33% | 21.58B | B | ||
-6.03% | 18.96B | A- | ||
-13.41% | 16.33B | B | ||
-40.50% | 16.96B | A- | ||
+6.64% | 14.14B | C+ | ||
+31.84% | 12.02B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MGNX Stock
- Ratings MacroGenics, Inc.